Core Viewpoint - Novo Nordisk's GLP-1 drug, semaglutide oral tablets for weight loss, has received FDA approval, marking it as the first oral GLP-1 weight loss medication approved globally. However, it is not yet approved for sale in China [3]. Group 1: Product Details - The initial dosage form approved is a 25mg oral tablet [4]. - Prior to FDA approval, all oral semaglutide was used for diabetes treatment, with significant dosage differences compared to weight loss indications. Non-diabetic users reported poor weight loss results [5][6]. - The approved oral semaglutide for weight loss has a starting dose of 1.5mg, increasing to 4mg after one month, then to 9mg in the third month, and a maintenance dose of 25mg thereafter [6]. Group 2: Clinical Efficacy - Clinical data published in NEJM indicates that the 25mg oral semaglutide can lead to an average weight loss of 16.6% over 64 weeks, with over 34.4% of patients achieving a weight loss of 20% or more, comparable to injection forms [7]. Group 3: Usage Guidelines and Limitations - Experts warn against taking multiple tablets at once to increase dosage, as the absorption rate of oral peptides is low (less than 1%), and exceeding the recommended dose can lead to serious side effects [8][9]. - The oral semaglutide must be taken on an empty stomach with strict dietary restrictions, unlike competitors like Orforglipron, which has higher bioavailability and fewer restrictions [10]. Group 4: Future Developments - Novo Nordisk is increasing its research on next-generation oral weight loss therapies, including a new drug, amycretin, which combines GLP-1 and insulin receptor agonists, showing potential for better clinical applications [10]. - There is currently no clinical registration progress for the oral semaglutide weight loss drug in China, and Novo Nordisk has not clarified its commercialization path in the region [10]. Group 5: Lifestyle Interventions - Experts emphasize that weight loss efficacy varies among individuals, and lifestyle interventions are fundamental to any weight loss strategy. Comprehensive and long-term lifestyle changes are recommended alongside any pharmacological treatments [11].

Core Viewpoint - Novo Nordisk's oral semaglutide for weight loss has received FDA approval, marking it as the first GLP-1 oral weight loss medication globally, although it is not yet approved in China [1][2]. Group 1: Product Details - The oral semaglutide for weight loss requires higher doses due to low bioavailability, with the approved dosage being 25mg, which is significantly higher than the previously available doses for diabetes treatment [1][3]. - The initial treatment dose is 1.5mg, increasing to 4mg after one month, then to 9mg in the third month, and finally maintaining at 25mg [3]. - Clinical data indicates that the 25mg oral semaglutide can lead to an average weight loss of 16.6% over 64 weeks, with over 34.4% of patients achieving a weight loss of 20% or more [3]. Group 2: Market and Usage Insights - Many users of oral semaglutide for weight loss are from the medical field, with most products sourced from Hong Kong and Japan, often through unofficial channels [2]. - Some users report dissatisfaction with the weight loss effects of oral semaglutide, leading them to switch to injectable forms for better results [2]. - Experts emphasize that prior to FDA approval, all oral semaglutide was intended for diabetes treatment, and using it for weight loss without diabetes may yield poor results [2]. Group 3: Safety and Administration - Experts warn against taking multiple pills at once to increase dosage, as this could lead to serious side effects without enhancing efficacy [4][5]. - The oral semaglutide must be taken on an empty stomach with strict dietary restrictions, which may limit its convenience compared to competitors like Orforglipron, which has higher bioavailability and fewer restrictions [5][6]. - Novo Nordisk is also advancing research on next-generation oral weight loss therapies, such as amycretin, which combines GLP-1 and insulin receptor agonism [6].